Reata Pharmaceuticals (NASDAQ:RETA – Free Report) had its target price boosted by Barclays from $98.00 to $110.00 in a report released on Wednesday, The Fly reports. A number of other equities research analysts have also issued reports on RETA. Robert W. Baird increased their target price on shares of Reata Pharmaceuticals from $40.00 to $85.00 […]
Reata Pharmaceuticals (NASDAQ:RETA – Free Report)‘s stock had its “reiterates” rating reiterated by equities researchers at 888 in a research report issued on Wednesday, Benzinga reports. RETA has been the subject of a number of other reports. Stifel Nicolaus lifted their price objective on Reata Pharmaceuticals from $105.00 to $115.00 and gave the company a […]
888 reiterated their reiterates rating on shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) in a research report released on Wednesday, Benzinga reports. RETA has been the subject of several other research reports. LADENBURG THALM/SH SH raised their price objective on shares of Reata Pharmaceuticals from $104.00 to $122.00 in a research note on Thursday. […]
Indian Americans organised the march in 20 major cities across the US including New York where they chanted 'Modi Modi', 'Vande Mataram' and 'Vande America'
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) – Stock analysts at SVB Leerink upped their FY2024 earnings per share (EPS) estimates for shares of Reata Pharmaceuticals in a research report issued to clients and investors on Monday, June 12th. SVB Leerink analyst J. Schwartz now forecasts that the company will post earnings per share of […]